{"id":68580,"date":"2026-04-09T13:42:55","date_gmt":"2026-04-09T08:12:55","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68580"},"modified":"2026-04-09T13:42:56","modified_gmt":"2026-04-09T08:12:56","slug":"solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/","title":{"rendered":"Solara Active Pharma Sciences Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook"},"content":{"rendered":"<p>Solara Active Pharma Sciences (NSE: SOLARA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 550 \u2014 against a 52-week high of Rs 820 and a 1-year return of -28% \u2014 the Q4 FY26 results will be a pivotal event for investors.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 780-850 Cr, with PAT expectations of Rs 30-55 Cr and margin projections of EBITDA 13-16%. This article covers the Solara Active Pharma Sciences Q4 results 2026 date, earnings estimates, five key performance factors, five risks, analyst ratings, and the most commonly searched investor questions.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Solara_Active_Pharma_Sciences_Q4_Results_2026_Date\" title=\"Solara Active Pharma Sciences Q4 Results 2026 Date\">Solara Active Pharma Sciences Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Solara_Active_Pharma_Sciences_Q4_FY26_Earnings_Estimates\" title=\"Solara Active Pharma Sciences Q4 FY26 Earnings Estimates\">Solara Active Pharma Sciences Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#5_Key_Factors_That_Will_Drive_Solara_Active_Pharma_Sciences_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Solara Active Pharma Sciences Q4 FY26 Performance\">5 Key Factors That Will Drive Solara Active Pharma Sciences Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Revenue_Momentum\" title=\"Revenue Momentum\">Revenue Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Margin_Trajectory\" title=\"Margin Trajectory\">Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#PAT_Quality\" title=\"PAT Quality\">PAT Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Management_Guidance_for_FY27\" title=\"Management Guidance for FY27\">Management Guidance for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Dividend_Declaration\" title=\"Dividend Declaration\">Dividend Declaration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#5_Risks_to_Watch_in_Solara_Active_Pharma_Sciences_Q4_FY26\" title=\"5 Risks to Watch in Solara Active Pharma Sciences Q4 FY26\">5 Risks to Watch in Solara Active Pharma Sciences Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#US_Tariff_and_Macro_Headwinds\" title=\"US Tariff and Macro Headwinds\">US Tariff and Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Earnings_Miss_Risk\" title=\"Earnings Miss Risk\">Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#FY27_Guidance_Below_Consensus\" title=\"FY27 Guidance Below Consensus\">FY27 Guidance Below Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#FII_Outflow_Continuation\" title=\"FII Outflow Continuation\">FII Outflow Continuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Sector_Regulatory_Risk\" title=\"Sector Regulatory Risk\">Sector Regulatory Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Solara_Active_Pharma_Sciences_Share_Price_and_Analyst_Ratings\" title=\"Solara Active Pharma Sciences Share Price and Analyst Ratings\">Solara Active Pharma Sciences Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_is_the_Solara_Active_Pharma_Sciences_Q4_results_2026_date\" title=\"What is the Solara Active Pharma Sciences Q4 results 2026 date?\">What is the Solara Active Pharma Sciences Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_is_the_Solara_Active_Pharma_Sciences_Q4_FY26_PAT_estimate\" title=\"What is the Solara Active Pharma Sciences Q4 FY26 PAT estimate?\">What is the Solara Active Pharma Sciences Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_is_Solara_Active_Pharma_Sciencess_share_price_ahead_of_Q4_results\" title=\"What is Solara Active Pharma Sciences&#8217;s share price ahead of Q4 results?\">What is Solara Active Pharma Sciences&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Will_Solara_Active_Pharma_Sciences_declare_a_dividend_in_Q4_FY26\" title=\"Will Solara Active Pharma Sciences declare a dividend in Q4 FY26?\">Will Solara Active Pharma Sciences declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Which_analysts_have_a_Buy_rating_on_Solara_Active_Pharma_Sciences\" title=\"Which analysts have a Buy rating on Solara Active Pharma Sciences?\">Which analysts have a Buy rating on Solara Active Pharma Sciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#What_were_Solara_Active_Pharma_Sciences_Q3_FY26_results\" title=\"What were Solara Active Pharma Sciences Q3 FY26 results?\">What were Solara Active Pharma Sciences Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Is_Solara_Active_Pharma_Sciences_a_good_investment_ahead_of_Q4_results\" title=\"Is Solara Active Pharma Sciences a good investment ahead of Q4 results?\">Is Solara Active Pharma Sciences a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/solara-active-pharma-sciences-q4-results-2026-date-revenue-pat-analyst-outlook\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_Q4_Results_2026_Date\"><\/span><strong>Solara Active Pharma Sciences Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Solara Active Pharma Sciences has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Results Date<\/strong><\/td><td><strong>Article<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Solara Active Pharma Sciences<\/td><td>May 2026 (Expected)<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Solara Active Pharma Sciences enters Q4 FY26 with expectations of 8-12% YoY revenue growth. Q4 is the final quarter of FY26 \u2014 it determines full-year performance, sets FY27 estimate baselines, and triggers final dividend announcements. At a 1-year return of -28%, this quarter&#8217;s results and FY27 guidance will be critical in determining whether the stock can sustain recovery momentum.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_Q4_FY26_Earnings_Estimates\"><\/span><strong>Solara Active Pharma Sciences Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-1024x536.jpg\" alt=\"Solara Active Pharma Sciences Q4 FY26 Earnings Estimates\" class=\"wp-image-68586\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 720 Cr<\/td><td>Rs 780-850 Cr<\/td><td>Volume + pricing<\/td><\/tr><tr><td>PAT<\/td><td>Rs 18 Cr<\/td><td>Rs 30-55 Cr<\/td><td>Operating leverage<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 12.6%<\/td><td>EBITDA 13-16%<\/td><td>Cost control<\/td><\/tr><tr><td>Key Growth Metric<\/td><td>Q3 trend<\/td><td>8-12% YoY revenue growth<\/td><td>Management execution<\/td><\/tr><tr><td>Dividend Estimate<\/td><td>\u2014<\/td><td>Nil expected<\/td><td>Board recommendation<\/td><\/tr><\/tbody><\/table><\/figure><p>A positive surprise on any two of the four key parameters \u2014 revenue, margin, guidance, and dividend \u2014 could drive a meaningful post-results re-rating.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Solara Active Pharma Sciences fundamentals<\/a> on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Solara_Active_Pharma_Sciences_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Solara Active Pharma Sciences Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Momentum\"><\/span><strong>Revenue Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts expect Rs 780-850 Cr in Q4 FY26 revenue (Q3: Rs 720 Cr). Q4 is seasonally important for the Pharma\/API sector, driven by year-end order execution and government capex push. The ability to convert the pipeline into recognised revenue will be the first test.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Trajectory\"><\/span><strong>Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 margin expectations are EBITDA 13-16%, versus EBITDA 12.6% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PAT_Quality\"><\/span><strong>PAT Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Net profit is estimated at Rs 30-55 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean, recurring profit print is most positively received by institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Management_Guidance_for_FY27\"><\/span><strong>Management Guidance for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The most consequential output will be FY27 guidance \u2014 revenue bands, margin targets, and capex plans. In the current global macro environment, credible and specific FY27 guidance will be valued more than usual by the market.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dividend_Declaration\"><\/span><strong>Dividend Declaration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Solara Active Pharma Sciences is expected to consider a final dividend of Nil expected. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Solara_Active_Pharma_Sciences_Q4_FY26\"><\/span><strong>5 Risks to Watch in Solara Active Pharma Sciences Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Tariff_and_Macro_Headwinds\"><\/span><strong>US Tariff and Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods has created macro uncertainty across Indian equities. For Solara Active Pharma Sciences, indirect impacts include FII outflows and potential earnings estimate cuts if global demand slows. A tariff negotiation breakthrough remains the most significant macro upside catalyst.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk\"><\/span><strong>Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Solara Active Pharma Sciences&#8217;s Q4 FY26 results miss estimates, the stock could correct sharply. Investors should monitor revenue versus the Rs 780-850 Cr estimate and PAT versus Rs 30-55 Cr as the two primary watchpoints on results day.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Below_Consensus\"><\/span><strong>FY27 Guidance Below Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If FY27 guidance falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current environment, forward guidance carries more weight than the reported quarter.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Outflow_Continuation\"><\/span><strong>FII Outflow Continuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>FIIs sold Rs 22,000 crore in Indian equities in a single week following the tariff announcement. Continued selling pressure would create headwinds for Solara Active Pharma Sciences regardless of company-specific fundamentals.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sector_Regulatory_Risk\"><\/span><strong>Sector Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma\/API sector faces evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Solara Active Pharma Sciences&#8217;s profitability beyond current consensus models.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Solara_Active_Pharma_Sciences_Share_Price_and_Analyst_Ratings\"><\/span><strong>Solara Active Pharma Sciences Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"536\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-1024x536.jpg\" alt=\"Solara Active Pharma Sciences Share Price and Analyst Ratings\" class=\"wp-image-68587\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-1024x536.jpg 1024w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-300x157.jpg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-768x402.jpg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-900x471.jpg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-600x314.jpg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-150x79.jpg 150w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot.jpg 1200w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure><p>Solara Active Pharma Sciences is trading at Rs 550 as of early April 2026, against a 52-week high of Rs 820 and a 52-week low of Rs 420. Market cap stands at Rs 2,200 Cr. The 1-year return of -28% reflects sector headwinds alongside company-specific factors.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Neutral<\/td><td>Rs 600<\/td><td>Ibuprofen + other API; debt overhang<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 650<\/td><td>Turnaround; new CEO driving change<\/td><\/tr><tr><td>JM Financial<\/td><td>Add<\/td><td>Rs 620<\/td><td>EBITDA recovery from FY25 trough<\/td><\/tr><tr><td>Emkay<\/td><td>Neutral<\/td><td>Rs 580<\/td><td>High leverage; cautious stance<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Solara Active Pharma Sciences&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Solara Active Pharma Sciences Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma\/API sector. Analysts project PAT of Rs 30-55 Cr and revenue of Rs 780-850 Cr. At a CMP of Rs 550 and analyst targets ranging from Rs 580 to Rs 600, the stock offers meaningful risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.<\/p><p>For more Q4 FY26 previews, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Solara_Active_Pharma_Sciences_Q4_results_2026_date\"><\/span><strong>What is the Solara Active Pharma Sciences Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Solara Active Pharma Sciences Q4 results 2026 date is May 2026 (Expected). The board will meet to approve audited Q4 FY26 financials and consider a dividend recommendation.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Solara_Active_Pharma_Sciences_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Solara Active Pharma Sciences Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Solara Active Pharma Sciences Q4 FY26 PAT at Rs 30-55 Cr, based on revenue of Rs 780-850 Cr and margin of EBITDA 13-16%. Actual results may differ from consensus.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Solara_Active_Pharma_Sciencess_share_price_ahead_of_Q4_results\"><\/span><strong>What is Solara Active Pharma Sciences&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Solara Active Pharma Sciences is trading at Rs 550. The 52-week high is Rs 820 and low is Rs 420. The 1-year return is -28% and market cap is Rs 2,200 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Solara_Active_Pharma_Sciences_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Will Solara Active Pharma Sciences declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Solara Active Pharma Sciences is expected to consider a final dividend of Nil expected at the Q4 FY26 board meeting on May 2026 (Expected).<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Solara_Active_Pharma_Sciences\"><\/span><strong>Which analysts have a Buy rating on Solara Active Pharma Sciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>YES Securities (Buy, Rs 650), JM Financial (Add, Rs 620) have positive ratings heading into Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Solara_Active_Pharma_Sciences_Q3_FY26_results\"><\/span><strong>What were Solara Active Pharma Sciences Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Solara Active Pharma Sciences reported Q3 FY26 revenue of Rs 720 Cr and PAT of Rs 18 Cr, with margin at EBITDA 12.6%. These form the baseline for Q4 FY26 estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Solara_Active_Pharma_Sciences_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Solara Active Pharma Sciences a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite and portfolio context. Solara Active Pharma Sciences has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor. Use the Univest Screener to assess fundamentals independently.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/mphasis-q4-results-2026\">Mphasis Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/mastek-q4-results-2026\">Mastek Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/cyient-q4-results-2026\">Cyient Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/kpit-technologies-q4-results-2026\">KPIT Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/zensar-technologies-q4-results-2026\">Zensar Technologies Q4 Results 2026: Date, Revenue Estimates, Key Catalysts &amp; Share Price Target<\/a><\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>Solara Active Pharma Sciences (NSE: SOLARA) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With the stock at Rs 550 \u2014 against a 52-week<\/p>\n","protected":false},"author":26,"featured_media":68585,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-68580","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"_edit_lock":["1775722491:26"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:8:{s:75:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Solara-Active-estimates.jpg\";a:2:{s:2:\"id\";i:68586;s:11:\"source_type\";s:13:\"media-library\";}s:84:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Solara-Active-estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:68586;s:11:\"source_type\";s:13:\"media-library\";}s:107:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates.jpg\";a:2:{s:2:\"id\";i:68586;s:11:\"source_type\";s:13:\"media-library\";}s:116:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134104\/Solara-Active-estimates-1024x536.jpg\";a:2:{s:2:\"id\";i:68586;s:11:\"source_type\";s:13:\"media-library\";}s:79:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Solara-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:68587;s:11:\"source_type\";s:13:\"media-library\";}s:88:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/Solara-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:68587;s:11:\"source_type\";s:13:\"media-library\";}s:111:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot.jpg\";a:2:{s:2:\"id\";i:68587;s:11:\"source_type\";s:13:\"media-library\";}s:120:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09134154\/Solara-Share-Price-Snapshot-1024x536.jpg\";a:2:{s:2:\"id\";i:68587;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["75"],"rank_math_focus_keyword":["Solara Active Pharma Sciences Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["68585"],"_edit_last":["26"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7641"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/09133947\/Solara-Active-Pharma.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68580","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68580"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68580\/revisions"}],"predecessor-version":[{"id":68593,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68580\/revisions\/68593"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68585"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}